Header Logo

Connection

Michael O'Dwyer to Follow-Up Studies

Back to Details
This is a "connection" page, showing publications Michael O'Dwyer has written about Follow-Up Studies.
Michael O'Dwyer
Connection Strength
0.084
Follow-Up Studies
  1. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
    View in: PubMed
    Score: 0.050
  2. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.